AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02999945 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SGA-enhanced nutrients
Description: Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
Study NCT05491070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular closure device (Angio-Seal, Progilde)
Description: In transfemoral TAVI, vascular closure devices were used for femoral artery wound closure, progilde and angio-seal can be used in wound closure. We aimed to compared the efficacy and safety of different vascular closure device in TAVI
Study NCT02999945 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IUGR-enhanced nutrients
Description: Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
Study NCT02999945 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SGA-standard nutrients
Description: Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
Study NCT02999945 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IUGR-standard nutrients
Description: Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
Study NCT00402766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Starting Dose: 60 mg/m\^2 by vein, Over 2 Hours
Study NCT01313845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amantadine sulfate
Description: infusion of amantadine sulfate 100mg/500ml/bottle over 3 hours twice a day
Study NCT00402766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Starting Dose: 300 mg PO Daily
Study NCT00402766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Starting Dose: 500 mg/m\^2 by vein, Over 40 Minutes
Study NCT00402766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg by vein given prior to Pemetrexed therapy and 4 mg given orally on Day 2 of each cycle.
Study NCT03824912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole Cream 2%
Description: Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
Study NCT03824912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole Cream 2% (G&W Laboratories Inc.)
Description: Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
Study NCT03824912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
Study NCT04462003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: 10 mg/12 h for 1 week followed by 5 mg/12 h
Study NCT01313845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: infusion of normal saline 500ml/bottle over 3 hours twice a day
Study NCT02979509 — intervention group
Intervention type: OTHER
Intervention: Endoscopic ultrasound- (EUS) guided tissue sampling
Description: EUS- guided tissue sampling of solid and/or cystic pancreatic and non-pancreatic lesions as part of their medical care.
Study NCT03294239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral extraction of bladder stone(s)
Description: Patients will have transurethral approach for management of their bladder stones. Either pneumatic or Holmium:YAG laser will be used for stone distentegration. Stone basket and/or Elics current evacuation will be used to retrieve stone fragments. Urethral catheter will be applied for 48 hours.
Study NCT03294239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous extraction of bladder stone(s)
Description: Patients will have percutaneous approach for management of their bladder stones. After initial cystoscopy a Foley's urethral catheter will be fixed for continuous irrigation. Then, the bladder will be filled to capacity with normal saline. Access to the distended bladder will be obtained by 10-gauge needle in the midline 1-2 cm above the pubic bone. Once suitable placement is confirmed with return of fluid, a guide wire will be passed through the needle into the bladder. Dilatation will be done using 8-10 Fr coaxial dilators then single fascial dilator with placement of 16 Fr Amplatz sheath as a working tract. No ultrasonic or fluoroscopic guidance will be used. Stone basket will be used to extract the stone. If the stones were larger than the used sheath, disintegration will be performed with a pneumatic lithotrite. Primary skin closure of the suprapubic stab wound by one stitch will be done and the urethral catheter will remain for 48 hours.
Study NCT00645528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin Education Class
Description: Participation in an Insulin Education Class at week 0 and week 2
Study NCT02239835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir (TPV) low dose
Study NCT02239835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir (TPV) high dose
Study NCT02239835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir low dose
Study NCT02239835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir high dose
Study NCT02239835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saquinavir
Study NCT03718572 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic cholecystectomy
Description: Surgical removal of Gall bladder using laparoscopy
Study NCT01327053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.
Study NCT04017923 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of nasal tip support in different age groups.
Description: Nasal tip resistances , were measured in all age groups with a digital Newton meter.
Study NCT03232645 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ablation procedure
Description: Cathater ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav Mifi OI ablation catheter
Study NCT00551915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AR51 (12, 10)
Description: vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
Study NCT00551915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR51 (3, 10)
Description: vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
Study NCT00156507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma education for parents of very low birth weight infants
Description: Asthma education is provided to parents of children in the experimental group prior to nicu discharge.
Study NCT00862030 — intervention group
Intervention type: PROCEDURE
Intervention: CT- simulation scan
Description: Patients who are receiving standard palliative radiotherapy planned under x-rays will also undergo 1 CT-simulation scan which they would otherwise not require. The planning x-rays and CT scan will then be compared dosimetrically
Study NCT00982072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: tacrolimus0.05mg/kg bd (levels 6-12ng/ml)
Study NCT00982072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: Prednisolone 1mg/kg maximum 60mg od
Study NCT02085772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples at 37-38 Weeks of amenorrhea
Study NCT00551915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR51 (6, 10)
Description: vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
Study NCT00551915 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PENTACEL™
Description: licensed vaccine for diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b, administered open-label
Study NCT00551915 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RECOMBIVAX HB™
Description: licensed vaccine for hepatitis, administered open-label
Study NCT05166278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: De-escalation training
Description: The intervention will include training on verbal and nonverbal de-escalation techniques. The training will be prepared according to the recommendations of the Beta Project of the American Association for Emergency Psychiatry, the World Health Organization Quality Rights training to act, unite and empower for mental health and a handbook for the use of de-escalation skills in a hospital setting by Amdur E. The first part of the education is based on theoretical backgrounds: aggressive behavior in a psychiatric patient, risk factors, focusing on factors that can be modified, communication, de-escalation. The second part is a practical workshop. The training will be 16 hour duration in total. A short handbook and a list of verbal and non-verbal approaches will be prepared for all staff members involved in the training.
Study NCT00096148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study NCT00096148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00096148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00096148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02085772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples at 41 Weeks of amenorrhea if prolonged pregnancy
Study NCT02136680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CASA Education
Description: Basic palliative care competencies for outpatient use.
Study NCT04462003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: 1mg/Kg/sc/12h
Study NCT02322567 — intervention group
Intervention type: OTHER
Intervention: medical records
Description: review of medical records
Study NCT03408756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Participants will receive methotrexate through oral or subcutaneous route of administration
Study NCT02111772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rhinovirus
Study NCT02111772 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rhinovirus
Study NCT01549093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine,Carboplatin,Endostar
Description: Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 48hours and the dosage is 7.5mg/m2\*2 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-6cycles.
Study NCT01549093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine(G) Carboplatin(C) Endostar
Description: Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-6cycles
Study NCT01549093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine(G) Carboplatin(C)
Description: Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; 21 days is one cycle.Continued using 2-6cycles
Study NCT01705184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles of each sequence
Study NCT01705184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7,5 mg/kg, IV (in the vein) on day 1 of each 21 day cycle until progression for each sequence
Study NCT01705184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles for the 1st sequence and until progression for the 2nd sequence.
Study NCT01059825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ertugliflozin
Description: Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days
Study NCT02085772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples at the time of delivery
Study NCT00745875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: 10mg oral tablet, once daily
Study NCT00745875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg2/m IV infusion
Study NCT00745875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: 500mg2/m IV infusion
Study NCT00745875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10mg oral tablet, once daily
Study NCT01602913 — intervention group
Intervention type: DRUG
Intervention: Pravastatin alone
Description: Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease.
Study NCT01059825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Ertugliflozin
Description: Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days
Study NCT01602913 — intervention group
Intervention type: DRUG
Intervention: Paroxetine alone
Description: Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
Study NCT01602913 — intervention group
Intervention type: DRUG
Intervention: Pravastatin and paroxetine combined
Description: Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease. Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
Study NCT00145587 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem Cell Transplantation
Description: An infusion of HLA partially matched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
Study NCT00145587 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Miltenyi Biotec CliniMACS
Description: Stem cell selection device
Study NCT00145587 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Systemic chemotherapy and antibodies
Description: Haploidentical stem cell transplant recipients will receive a reduced intensity conditioning regimen consisting of OKT-3, Fludarabine, Thiotepa , and Melphalan followed by an infusion of a T-cell depleted donor stem cell product. Rituximab will be administered within 24 hours of the infusion in an effort to prevent post transplantation lymphoproliferative disorders (PTLPD). In addition to T-cell depletion of the donor product, cyclosporine will be provided as prophylaxis for (GVHD)Graft versus Host Disease~Recipients of a matched sibling donor product will receive a myeloablative conditioning regimen consisting of busulfan and cyclophosphamide. Cyclosporine will be administered for GVHD prophylaxis.
Study NCT04359017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% Injectable Solution
Description: The lidocaine will be injected into the fracture hematoma using buffered 1% lidocaine solution at a dose of 2.5 mg/kg (0.25 mL/kg), maximum dose 100 mg (10 mL). Using a 30-gauge needle to minimize pain, a small skin wheal of lidocaine will be injected over the fracture site. A 21-gauge needle will then be attached to the lidocaine filled syringe and passed through the skin wheal used to inject the lidocaine into the fracture hematoma. To confirm the needle is in the fracture hematoma, a small amount of blood from the hematoma will be aspirated into the syringe filled with lidocaine before injecting the lidocaine, as in standard practice.
Study NCT01534546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin capecitabine
Description: capecitabine：1000 mg/m2 ，bid, d1\~14 oxaliplatin：130mg/m2，iv drip for 2h，d1
Study NCT01534546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin S-1
Description: S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
Study NCT01534546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin S-1
Description: S-1: 40\~60mg bid，d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1 S-1 monotherapy as the same dose and schedule of the above
Study NCT01337141 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: 7 face-to-face visits.
Study NCT01337141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telecare system
Description: 5 telematic visits and 2 face-to-face visits.
Study NCT05040828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.
Description: Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
Study NCT05040828 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast Sodium Tablets 10mg quaque die orally was administered after peak pollen count.
Description: 10mg quaque die orally was administered after peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
Study NCT01059825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Ertugliflozin
Description: Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days
Study NCT01059825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 1 mg
Description: Tablet, 1 mg, once daily for 84 days
Study NCT06606340 — intervention group
Intervention type: DRUG
Intervention: Eteplirsen
Description: No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
Study NCT06606340 — intervention group
Intervention type: DRUG
Intervention: Golodirsen
Description: No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
Study NCT06606340 — intervention group
Intervention type: DRUG
Intervention: Casimersen
Description: No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
Study NCT01059825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days
Study NCT02455518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/acetaminophen
Study NCT05040828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No oral drug therapy throughout the pollen period
Description: Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
Study NCT02403375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek Insight Pump System
Description: Continuous subcutaneous insulin infusion pump
Study NCT02455518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone/acetaminophen
Study NCT02455518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine/acetaminophen